Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer

Grapin, Mathieu; Coutant, Charles; Riedinger, Jean-Marc; Ladoire, Sylvain; Brunotte, François; Cochet, Alexandre; Humbert, Olivier

doi:10.1016/j.ejrad.2019.02.005

Cited by 13 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These two factors were combined to create three patient groups with varied chances of getting breast-conserving surgery. According to their findings, the likelihood of undergoing breast-conserving surgery steadily improved from 29% in the group with the worst prognosis (low total breast volume and poor tumor shrinking) to 82% in the group with the best prognosis (high total breast volume and significant tumor metabolic shrinkage) [ 57 ].…”

Section: Resultsmentioning

confidence: 99%

Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response

Castorina,

Comis,

Prestifilippo

et al. 2023

JCM

View full text Add to dashboard Cite

The advent of hybrid Positron Emission Tomography/Computed Tomography (PET/CT) and PET/Magnetic Resonance Imaging (MRI) scanners resulted in an increased clinical relevance of nuclear medicine in oncology. The use of [18F]-Fluorodeoxyglucose ([18F]FDG) has also made it possible to study tumors (including breast cancer) from not only a dimensional perspective but also from a metabolic point of view. In particular, the use of [18F]FDG PET allowed early confirmation of the efficacy or failure of therapy. The purpose of this review was to assess the literature concerning the response to various therapies for different subtypes of breast cancer through PET. We start by summarizing studies that investigate the validation of PET/CT for the assessment of the response to therapy in breast cancer; then, we present studies that compare PET imaging (including PET devices dedicated to the breast) with CT and MRI, focusing on the identification of the most useful parameters obtainable from PET/CT. We also focus on novel non-FDG radiotracers, as they allow for the acquisition of information on specific aspects of the new therapies.

show abstract

Section: Resultsmentioning

confidence: 99%

Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response

Castorina,

Comis,

Prestifilippo

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…In 77 patients with luminal/HER2-negative breast cancer that underwent [ 18 F]FDG-PET at baseline and after one cycle of NAC, the probability of breast conserving surgery could be predicted using three subgroups with different odds for breast conserving surgery based on volumetric measures ( p = 0.001). 72 Even though currently these findings are insufficient to recommend routine implementation in clinical practice, future studies could evaluate selection of patients for surgical intervention with (metabolic change on) [ 18 F]FDG-PET as biomarker to predict local response, based on these results. Another cornerstone of early breast cancer treatment is radiation therapy, which can be given post-operatively after breast-conserving surgery to the breast and lymph nodes to reduce risk of in-breast or in lymph node relapse, respectively.…”

Section: [ 18 F]fdg-pet In Early Breast Cancermentioning

confidence: 99%

Molecular imaging as biomarker for treatment response and outcome in breast cancer

et al. 2023

View full text Add to dashboard Cite

Molecular imaging, such as positron emission tomography (PET), is increasingly used as biomarker to predict and assess treatment response in breast cancer. The number of biomarkers is expanding with specific tracers for tumour characteristics throughout the body and this information can be used to aid the decision-making process. These measurements include metabolic activity using [18F]fluorodeoxyglucose PET ([18F]FDG-PET), oestrogen receptor (ER) expression using 16α-[18F]Fluoro-17β-oestradiol ([18F]FES)-PET and human epidermal growth factor receptor 2 (HER2) expression using PET with radiolabelled trastuzumab (HER2-PET). In early breast cancer, baseline [18F]FDG-PET is frequently used for staging, but limited subtype-specific data reduce its usefulness as biomarker for treatment response or outcome. Early metabolic change on serial [18F]FDG-PET is increasingly used in the neo-adjuvant setting as dynamic biomarker to predict pathological complete response to systemic therapy, potentially allowing de-intensification or step-up intensification of treatment. In the metastatic setting, baseline [18F]FDG-PET and [18F]FES-PET can be used as biomarker to predict treatment response, in triple-negative and ER-positive breast cancer, respectively. Metabolic progression on repeated [18F]FDG-PET appears to precede progressive disease on standard evaluation imaging; however, subtype-specific studies are limited and more prospective data are needed before implementation in clinical practice. Even though (repeated) [18F]FDG-PET, [18F]FES-PET and HER2-PEt all show promising results as biomarkers to predict therapy response and outcome, for eventual integration into clinical practice, future studies will have to clarify at what timepoint this integration has to optimally take place.

show abstract

“…The purpose of NAC is to reduce the tumor's size and improve surgical outcomes, cosmetic results, and chances of conservative breast surgery, control tumor progression and observe tumor sensitivity (or resistance) to the chosen treatment regimen (1)(2)(3)(4). Several studies have suggested better survival outcomes in patients achieving complete pathological remission than in patients with residual or progressive disease at the time of definitive surgery (5,6). However, the mechanisms of primary resistance and strategies to overcome those are a matter of intense research.…”

Section: Introductionmentioning

confidence: 99%

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes

et al. 2022

View full text Add to dashboard Cite

Combination of breast imaging parameters obtained from 18F-FDG PET and CT scan can improve the prediction of breast-conserving surgery after neoadjuvant chemotherapy in luminal/HER2-negative breast cancer

Cited by 13 publications

References 43 publications

Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response

Innovations in Positron Emission Tomography and State of the Art in the Evaluation of Breast Cancer Treatment Response

Molecular imaging as biomarker for treatment response and outcome in breast cancer

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes

Contact Info

Product

Resources

About